BeiGene (STU:49B) Short-Term Debt : €761 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene Short-Term Debt?

BeiGene's Short-Term Debt for the quarter that ended in Mar. 2024 was €761 Mil.

BeiGene's quarterly Short-Term Debt increased from Sep. 2023 (€308 Mil) to Dec. 2023 (€631 Mil) and increased from Dec. 2023 (€631 Mil) to Mar. 2024 (€761 Mil).

BeiGene's annual Short-Term Debt declined from Dec. 2021 (€378 Mil) to Dec. 2022 (€311 Mil) but then increased from Dec. 2022 (€311 Mil) to Dec. 2023 (€631 Mil).

BeiGene Short-Term Debt Historical Data

The historical data trend for BeiGene's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Short-Term Debt Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

275.38

378.40

310.55

631.23

BeiGene Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															263.21	388.63	307.86	631.23	760.81

BeiGene Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

BeiGene Short-Term Debt Related Terms

Thank you for viewing the detailed overview of BeiGene's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (STU:49B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (STU:49B) Headlines

No Headlines